BioAdvance News Portfolio News Venatorx Pharmaceuticals

CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea

By WebmasterNovember 25, 2019November 1st, 2024No Comments

CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea
Funding represents 51st CARB-X Award, and 2nd CARB-X Award for VenatoRx

See more here

Previous PostHarvard Pilgrim Health Care And Ride Health Collaborate To Provide Health Care-Related Transportation For Medicare Members In Two States
Next PostPalvella Therapeutics Commences Phase 3 Portion of Phase 2/3 Pivotal Study of PTX-022 in Pachyonychia Congenita

CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostHarvard Pilgrim Health Care And Ride Health Collaborate To Provide Health Care-Related Transportation For Medicare Members In Two States

Next PostPalvella Therapeutics Commences Phase 3 Portion of Phase 2/3 Pivotal Study of PTX-022 in Pachyonychia Congenita